Vasculitis News and Research

Latest Vasculitis News and Research

Study shows ADA2 is a sensitive, specific biomarker for macrophage activation syndrome

According to new research findings presented at the 2019 ACR/ARP Annual Meeting, adenosine deaminase 2 (ADA2) in the peripheral blood is a sensitive, specific biomarker for macrophage activation syndrome, a potentially life-threatening complication of systemic juvenile idiopathic arthritis (systemic JIA)

10 Nov 2019

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

An international, multicenter phase II clinical trial is evaluating the efficacy and safety of mavrilimumab co-administered with a 26-week corticosteroid taper in patients with giant cell arteritis.

26 Sep 2019

Survey says half of people with rheumatoid disease struggle to pay for treatment

Rheumatoid disease encompasses inflammatory conditions that affect the joints, muscle, bones, and organs. A new study found that despite 90 of patients have health insurance, nearly 60 percent said that they are struggling to afford medication or treatment in the last year.

16 Sep 2019

Tiny fat bubbles hold key to rebooting the immune system and calming disease process

People living with inflammatory autoimmune disease could benefit from an 'immune system reboot', and researchers have isolated specific cells to target.

7 Sep 2019

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

After a cancer patient receiving an immunotherapy developed encephalitis and died 18 months into treatment, researchers at Vanderbilt-Ingram Cancer Center investigated why the complication occurred, performing a molecular analysis of the disease's pathology and mining data to determine the incidence of similar occurrences.

22 Jul 2019

Promising methods for early detection and treatment of rheumatoid arthritis

Rheumatoid arthritis is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs. In this themed issue of Clinical Therapeutics, published by Elsevier, experts review multiple aspects of RA detection and intervention with the overall goal of moving the field closer to developing effective preventive measures.

10 Jun 2019

Radiation-induced vascular damage could be treated with IL-1 inhibitors

Radiation therapy against cancer can increase the risk of cardiovascular disease much later in life, as the radiation causes chronic inflammation of the exposed blood vessels.

14 May 2019

Association found between gene variant and lung disease in the form of systemic vasculitis

University of Tsukuba-led team reveals the association between a gene variant and a lung disease in the form of systemic vasculitis particularly prevalent in the Japanese, potentially providing a target for future therapies.

13 Mar 2019

Researchers reveal promising biomarker for vascular disease relapse

Researchers at Okayama University report in the journal Arthritis & Rheumatology that monitoring a particular antigen can be used for predicting relapse of the vascular disease AAV.

28 Feb 2019

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Checkpoint inhibitor therapy is a form of cancer treatment immunotherapy currently under research. The therapy targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions, which tumors can use to protect themselves from attacks by the immune system.

18 Jan 2019

Meta-analysis reveals effective treatment options for urticarial vasculitis

What treatments are available for patients with the rare inflammatory disease known as urticarial vasculitis? How effective are these treatments? Researchers from Charité - Universitätsmedizin Berlin embarked on a systematic review and meta-analysis to address these questions.

30 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.

22 Oct 2018

Health Care Apps and the Empowered Patient

An interview with Evergreen Life, discussing the importance of patient empowerment and how technology is allowing the NHS take a holistic approach to care.

From Evergreen Life 12 Sep 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Pfizer announces FDA approval of biosimilar to Neupogen

Pfizer Inc. today announced that the United States Food and Drug Administration has approved NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim), for all eligible indications of the reference product.

23 Jul 2018

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

Rheumatoid Arthritis: A systematic approach (edited by Dr. Syuichi Koarada) comprehensively covers each aspect of the pathology, diagnosis and treatment of rheumatoid arthritis.

26 Jun 2018

Vasculitis News and Research

Latest Vasculitis News and Research

Study shows ADA2 is a sensitive, specific biomarker for macrophage activation syndrome

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

Survey says half of people with rheumatoid disease struggle to pay for treatment

Tiny fat bubbles hold key to rebooting the immune system and calming disease process

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

Promising methods for early detection and treatment of rheumatoid arthritis

Radiation-induced vascular damage could be treated with IL-1 inhibitors

Association found between gene variant and lung disease in the form of systemic vasculitis

Researchers reveal promising biomarker for vascular disease relapse

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Meta-analysis reveals effective treatment options for urticarial vasculitis

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Health Care Apps and the Empowered Patient

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Pfizer announces FDA approval of biosimilar to Neupogen

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vasculitis News and Research

Latest Vasculitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in